Tubulis GmbHMunich-Martinsried-based biotech Tubulis has closed a €308 million (USD 361 million) Series C financing round – the largest of its kind for a still existing European biotechnology company at the Series C stage and also the world’s largest financing for a private ADC (antibody–drug conjugate) developer. The attractivity lays in the technologyplatform of linking the payload.
Tag Archive for: cancer
Owlstone Medical Ltd.Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HHS in the US is moving in a different direction?
ForbionBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. Ltd. in exchange for the development and marketing rights to the low-molecular-weight inflammation blocker FXS6837.
adpbe stock photos - David A Litman Bayer AG’s Pharmaceuticals division in Berlin has expanded its oncology pipeline through a licensing and collaboration agreement with US-based Kumquat Biosciences Inc., which may yield up to US$1.3bn in total consideration. Should Kumquat successfully complete its high-risk Phase Ia clinical study targeting the common KRAS G12D mutation, Bayer will assume responsibility for further development and global commercialisation of the candidate.
Jovanche Vitanovski/123rf.comParis-based One Biosciences, a pioneering “techbio” company at the intersection of artificial intelligence and oncology, has announced a €15 million Series A funding round to accelerate the clinical application of its flagship technology.
BioNTechBioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
adobe stock - JHVEPhoto Boehringer Ingelheim and synthetic lethality specialist Tessellate Bio have entered into an €500m biobucks global license agreement on oral first-in-class cancer treatments.
adobe stock - peterschreiber.mediaThe British company Semarion Ltd and US start-ups n6 Tec Inc and Portal Biotechnologies Inc were honoured with the New Product Award at the SLAS Conference 2025 in San Diego. The award, presented by the Society for Automation & Drug Screening, recognises pioneering technologies with the potential to transform the industry.
SLASItalian InSimili Srl has been awarded the Ignite Award for the most innovative start-up company in the lab automation sector. The US$5,000 prize was presented by the Society for Laboratory Automation and Screening (SLAS) to the company at SLAS 2025, the leading international conference for lab automation and drug screening
UCB SABelgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.